

Prednisone
Essential medicine status
General description

INN
Prednisone
Medicine type
Chemical agent
EML status history

First added in 2021 ([TRS 1035](#)) for [Allergic or hypersensitivity conditions of unspecified type](#)
Changed in 2021 ([TRS 1035](#)) for [Follicular lymphoma](#)
Changed in 2021 ([TRS 1035](#)) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)
Changed in 2021 ([TRS 1035](#)) for [Plasma cell myeloma](#)
Changed in 2021 ([TRS 1035](#)) for [Malignant neoplasms of prostate](#)
Changed in 2021 ([TRS 1035](#)) for [Lymphoid leukaemia, not elsewhere classified](#)
Changed in 2021 ([TRS 1035](#)) for [Diffuse large B-cell lymphoma, not otherwise specified](#)
Changed in 2021 ([TRS 1035](#)) for [Hodgkin lymphoma](#)
Changed in 2023 ([TRS 1049](#)) for [Langerhans cell histiocytosis](#)
Changed in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-positive](#)
Changed in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-negative](#)
Added in 2025 ([TRS 1064](#)) for [Adrenocortical insufficiency](#)

Therapeutic equivalent for
[prednisolone](#) for [Allergic or hypersensitivity conditions of unspecified type](#)
[prednisolone](#) for [Follicular lymphoma, unspecified](#)
[prednisolone](#) for [Lymphoid leukaemia, not elsewhere classified](#)
[prednisolone](#) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)
[prednisolone](#) for [Diffuse large B-cell lymphoma, not otherwise specified](#)
[prednisolone](#) for [Hodgkin lymphoma, unspecified](#)
[prednisolone](#) for [Anaplastic large cell lymphoma, ALK-negative](#)
[prednisolone](#) for [Plasma cell myeloma](#)
[prednisolone](#) for [Malignant neoplasms of prostate, unspecified](#)
[prednisolone](#) for [Langerhans cell histiocytosis](#)
[prednisolone](#) for [Anaplastic large cell lymphoma, ALK-positive](#)
[prednisolone](#) for [Adrenocortical insufficiency](#)

Wikipedia
[Prednisone](#)
DrugBank
[Prednisone](#)